#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Guillain-Barre syndrome Glioblastoma Noonan syndrome Oesophageal atresia White matter lesion Aspergillus infection Cluster headache Anaemia Thymic carcinoma Activated PI3 kinase delta syndrome Systemic scleroderma Ehlers-Danlos syndrome Diffuse large B-cell lymphoma refractory Germ cell cancer Demyelination More trials…

    Learn about Rare Diseases

    Idiopathic pulmonary fibrosis – Diagnostics Splenic marginal zone lymphoma – Treatment Angelman’s syndrome – Basic Information Ocular melanoma – Basic Information Choroid melanoma Wiskott-Aldrich syndrome – Trials in Disease Immunodeficiency congenital – Trials in Disease CADASIL – Diagnostics Mantle cell lymphoma refractory – Life with Disease Behcet’s syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Perflubutane Oxaliplatin Immunostimulants Berotralstat Elvn-002-1 Ziltivekimab Omp10 Piritramide Amoxicillin Trihydrate Cefepime Dexamethasone Isonicotinate Betula Pendula Pollen Extract INSULIN DETEMIR Clarithromycin Palmidrol Bms-986340 SRSD107 Belumosudil Mesilate Vusolimogene Oderparepvec GSK5784283 More therapies…

    Learn about Your Condition

    Tendon rupture Rubella Pharyngeal cancer stage II Hereditary angioedema Giardiasis Inner ear disorder Papulopustular rosacea Food allergy Oesophageal atresia Ejection fraction normal Hypertension Anal abscess Neoplasm Stress urinary incontinence Peritoneal cancer index More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer

  • Study on Enzalutamide and Talazoparib for Treating Metastatic Hormone-Naïve Prostate Cancer in Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Enzalutamide
    • Talazoparib
    Spain

  • Study on Hormonal Treatment with Leuprorelin Acetate for Prostate Cancer Patients at High Risk of Recurrence After Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Leuprorelin Acetate
    France

  • Study on Enzalutamide for Patients with Localized Prostate Cancer Undergoing Robotic-Assisted Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Enzalutamide
    Spain

  • Study of Apalutamide for Patients with High-Risk Prostate Cancer After Prostate Removal

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Apalutamide
    Austria Germany

  • Study on Enzalutamide and Drug Combination for High-Risk Localized Prostate Cancer Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Flutamide
    • Nilutamide
    • Bicalutamide
    Austria Ireland Spain

  • Study of Pembrolizumab and 68GA-PSMA HBED-CC in Patients with High-Risk Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • 2-[[5-[3-[[6-[[(5S)-5-Carboxy-5-[[(1S)-1,3-Dicarboxypropyl]Carbamoylamino]Pentyl]Amino]-6-Oxohexyl]Amino]-3-Oxopropyl]-2-Oxidophenyl]Methyl-[2-[[5-(2-Carboxyethyl)-2-Oxidophenyl]Methyl-(Carboxylatomethyl)Amino]Ethyl]Amino]Acetate:gallium-68(3+) Hydron
    • Pembrolizumab
    Italy
Previous Page
1 … 11 12 13 14 15 … 17
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!